Register-for-Webinars Register-for-Webinars
Register for Webinars

News & Knowledge

Hormone Metabolism Simplified: A Practical HuMap™ Guide for Busy Integrative Clinicians

Presented by Ruth Hobson, ND | March 4, 2026 at 12 PM Pacific

Hormone and metabolite testing offers powerful clinical insight, but for many practitioners, the reports can feel overwhelming and time consuming to interpret. When clinical days are full, translating complex hormone data into clear, confident treatment decisions can be a challenge.

Join Dr. Ruth Hobson for a practical, clinician focused walkthrough of the HuMap™, designed to help integrative practitioners quickly make sense of hormone metabolism without getting lost in the data. This concise webinar will focus on the four key hormone pathways; progesterones, corticoids, androgens, and estrogens, showing you how to identify clinically meaningful patterns that inform treatment decisions in real time.

You'll learn how to efficiently interpret hormone metabolism, recognize patterns linked to common concerns such as PCOS, metabolic dysfunction, sexual health issues, breast and prostate health, and optimize both endogenous and exogenous hormone strategies. This session emphasizes clinical efficiency, decision-making confidence, and actionable takeaways you can apply immediately making hormone testing a tool that works for your practice, even on your busiest days.

Learning Objectives:

  • Evaluate the structure and key components of the HuMap™ report to extract clinically actionable insights for individualized patient management.
  • Interpret hormone metabolism patterns identified by HuMap™ and their clinical relevance to endocrine-related conditions, including breast and prostate health, PCOS, metabolic dysfunction, etc.
  • Assess the metabolism and bioavailability of exogenous hormones using HuMap™ testing to optimize the efficacy, tolerability, and safety of bioidentical hormone therapies.
  • Apply evidence informed strategies to modulate enzymatic activity and optimize hormone metabolism for improved outcomes and risk reduction.

Register here:
12:00 PM PST

Beyond Traditional Lipids: Case-Driven Cardiometabolic Risk Assessment with Advanced Biomarkers

Presented by Melody Hartzler, PharmD | March 11, 2026 at 12 PM Pacific

Cardiovascular disease remains the leading cause of morbidity and mortality worldwide, yet traditional lipid panels frequently fail to capture key drivers of cardiometabolic risk. This case-based, evidence-anchored session equips clinicians with practical strategies to interpret and act on the Doctor's Data Cardiometabolic Profile, integrating traditional lipid markers with advanced biomarkers of glycemic control, insulin resistance, inflammation, oxidative stress, adipose signaling, renal function, and lipoprotein physiology.

Through real-world patient cases, participants will learn how to interpret markers including Apolipoproteins A1 and B, small dense LDL, oxidized LDL, PLAC® (Lp-PLA2 activity), Lipoprotein(a), hs-CRP, homocysteine, insulin, glucose, 1,5-anhydroglucitol (1,5-AG), leptin, adiponectin, the leptin-to-adiponectin ratio, cystatin C, creatinine/eGFR, and comprehensive cholesterol fractions to uncover cardiometabolic risk that extends beyond LDL-centric models.

The session emphasizes pattern recognition and protocol-driven care, translating biomarker abnormalities into targeted lifestyle, nutraceutical, and-when appropriate-pharmacologic strategies aimed at improving metabolic flexibility, vascular health, and long-term cardiovascular outcomes.

Upon completion, participants will be able to:

  • Describe the clinical relevance of advanced cardiometabolic biomarkers, including apolipoproteins (A1 and B), small dense LDL, oxidized LDL, PLAC® activity, Lipoprotein(a), inflammatory markers (hs-CRP, homocysteine), glycemic and insulin resistance markers (glucose, insulin, 1,5-AG), adipokines (leptin, adiponectin, leptin-to-adiponectin ratio), and renal markers (cystatin C, creatinine/eGFR), and how they complement traditional lipid testing.
  • Interpret real patient case data from the Doctor's Data Cardiometabolic Risk Profile to identify patterns consistent with atherogenic dyslipidemia, metabolic dysfunction, adipose signaling imbalance, oxidative stress, and systemic inflammation.
  • Apply evidence-based interventions tailored to specific biomarker abnormalities, including lifestyle and nutrition protocols, physical activity strategies, weight management approaches, targeted supplementation, and appropriate medication considerations when indicated.
  • Construct individualized cardiometabolic care plans that integrate advanced biomarker findings with traditional lipid values and established cardiovascular risk frameworks to more precisely assess and mitigate patient risk.

Register here:
12:00 PM PST
DeeDee, Doctor's Data Virtual Assistant
− ✕
Ask our AI